Product Data Sheet

Product Name: PRT062607 (P505-15)
Cat. No.: GC31819

Chemical Properties

Cas. No.	1370261-96-3		
SMILES	NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O		
Formula	$C_{19}H_{23}N_9O$	M.Wt	393.45
Solubility	DMF: 50 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 25 mg/ml,Ethanol: 10 mg/ml	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	PRT062607 (P505-15)		

Background

BIIB-057 is a potent inhibitor of the non-receptor tyrosine kinase Syk (IC_{50} = 1 nM).[1] It displays at least 80-fold selectivity for Syk over other kinases. BIIB-057 blocks B cell receptor-mediated cell signaling and activation in whole blood (IC_{50}s = 0.27 and 0.28 ? M, respectively), as well as Fc? receptor 1-mediated basophil degranulation (IC_{50} = 0.15 ?M).[1] It antagonizes chemokine production, cell migration, and survival of chronic lymphocytic leukemia (CLL) cells after B cell receptor activation and synergistically enhances the action of fludarabine in killing CLL cells.[2,3] BIIB-057 is orally bioavailable, as it produces dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis.[1] It also prevents splenomegaly and inhibits non-Hodgkin lymphoma tumor growth in a xenograft model.[3]

1.Coffey, G., DeGuzman, F., Inagaki, M., et al.Specific inhibition of spleen tyrosine kinase

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritisJ. Pharmacol. Exp. Ther.340(2)350-359(2012) 2.Hoellenriegel, J., Coffey, G.P., Sinha, U., et al.Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migrationLeukemia26(7)1576-1583(2012) 3.Spurgeon, S.E., Coffey, G., Fletcher, L.B., et al.The selective Syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemiaJ. Pharmacol. Exp. Ther.344(2)378-387(2015)

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA